Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The rationale of the study is to collect structured data in the neuropsychological, clinical neuroradiologic and neurorehabilitation fields in children/young people affected by congenital and juvenile myotonic dystrophy. Children affected by the congenital form (CDM1) present important brain alterations present since birth while, on the contrary, patients with the adult form of DM1 often present a degenerative, slowly progressive neurocognitive picture. Promising therapies that aim to correct the molecular mechanism underlying the symptoms of adult forms of DM1 are under development, but their potential role at the level of the nervous system and in particular in forms of CDM1 (which appears to be a distinct disorder of neuronal development) is also to be clarified.
To this end, a better definition of neurocognitive profiles and their evolution is essential for the purposes of evaluating the effectiveness of experimental therapies.
A. Recruitment of patients with a defined diagnosis of Myotonic Dystrophy type 1 (see following inclusion and exclusion criteria)
B) Clinical and cognitive evaluation
neurological and neuromuscular examination, compilation of the MIRS-muscle scale and EPWORTH scale-daytime sleepiness (1 session of approximately 1 hour);
administration of a neuropsychological battery, in order to define the level of cognitive functioning and to frame a detailed function-specific profile (multiple sessions to be defined based on the collaboration of the patients) investigating the following areas:
psychiatric examination and administration of psychological tests (MMPI-2, Minnesota Multiphasic Personality Inventory 2) to investigate any psychopathologies (behavioral disorders, anxiety disorders, developmental disorders, hyperactivity/attention deficit) and to define the psychological-behavioral profile and adaptive (Vineland Adaptive Behavioral Scale)
neuroimaging examination through Morphological magnetic resonance and Diffusor Tensor imaging and Voxel Based Morphometry protocols
based on the clinical conditions, a cardiological evaluation will also be carried out (including instrumental tests such as Electrocardiogram ECG, echocardiogram and 24-hour ECG) and pneumological evaluation (with recording of nocturnal oximetry, spirometry), eye examination, phoniatric examination and logopedic evaluation (aimed at evaluating chewing/swallowing)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Myotonic Dystrophy type 1 | Myotonic Dystrophy type 1 -congenital form Myotonic Dystrophy type 1-infantile form |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| neurocognitive evaluations | Diagnostic Test | clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance |
|
| Measure | Description | Time Frame |
|---|---|---|
| Motor function evaluation by Muscular Impairment Rating Scale | Muscular Impairment Rating Scale (MIRS) in assessing patients with myotonic dystrophy type 1 (DM1). The MIRS is a ordinal five-point rating scale, where grade 1 = no clinical muscular impairment; grade 2 = early muscular impairment (clinical myotonia, facial weakness, and weakness of neck flexors) without limb weakness; grade 3 = distal weakness; grade 4 = mild to moderate (3 ≤ core < 5) proximal weakness; grade 5 = severe (MRC score<3)proximal weakness proximal weakness | through study completion,an average of 2 years |
| cognitive evaluation by Wechsler Intelligence scale | Wechsler Intelligence scale: mean score 100 SD 15 (SD: Standard Deviation):deficiency when 2 Standard Deviation below average) | through study completion,an average of 2 years |
| cognitive evaluation by Raven Matrices | Raven Matrices , Z scores=/> 0,00 (in range); Z scores =/< -2,00 (deficiency) | through study completion,an average of 2 years |
| cognitive evaluation by Continous Performance Test 3 | Continous Performance Test 3: T mean Scores 50 SD 10 (SD: standard deviation) (T=45-59 in range; T =/>60 below range) | through study completion,an average of 2 years |
| cognitive evaluation by Trail Making Test A-B | Trail Making Test A-B: Z scores=/> 0,00 (in range); Z scores =/< -2,00 (deficiency) | through study completion,an average of 2 years |
| cognitive evaluation by Digit Span and CORSI Test | Digit Span and CORSI Test:Z scores=/> 0,00 (in range); Z scores =/< -2,00 (deficiency) |
| Measure | Description | Time Frame |
|---|---|---|
| clinical evaluation by Epworth Sleepiness Scale | Epworth Sleepiness Scale: scores from 0 to 24; above 10, clinical risk. | through study completion,an average of 2 years |
| cognitive evaluation by Wisconsin Card Sorting Test |
Not provided
Inclusion criteria:
Exclusion criteria
Not provided
Not provided
Patients with a defined diagnosis of MYotonic Dystrophy type 1, congenital and juvenile form
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Maria G D'Angelo, MD | Contact | 031877870 | +39 | grazia.dangelo@lanostrafamiglia.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maria Grazia D'Angelo | Recruiting | Bosisio Parini | Lecco | 23842 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009223 | Myotonic Dystrophy |
| ID | Term |
|---|---|
| D009136 | Muscular Dystrophies |
| D020966 | Muscular Disorders, Atrophic |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| through study completion,an average of 2 years |
| cognitive evaluation by Rey Figure test | Rey Figure test: Z scores=/> 0,00 (in range); Z scores =/< -2,00 (deficiency): | through study completion,an average of 2 years |
Wisconsin Card Sorting Test: mean score 100 SD 15 (SD: standard deviation) : deficiency when 2 Standard Deviation below average
| through study completion,an average of 2 years |
| cognitive evaluation by Tower of London test | Tower of London:mean score 100 SD 15 deficiency when 2 Standard Deviation below average) | through study completion,an average of 2 years |
| cognitive and behavioral evaluation by Minnesota Multiphasic Personality Inventory | Minnesota Multiphasic Personality Inventory- MMPI 2: mean score 50 SD 10 ((SD: standard deviation) | through study completion,an average of 2 years |
| cognitive and behavioral evaluation by Vineland Adaptive Behavior Scales | Vineland Adaptive Behavior Scales mean score 100 SD 15 (SD: standard deviation) :deficiency when 2 Standard Deviation below average | through study completion :an average of 2 years |
| D020967 | Myotonic Disorders |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D009422 | Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |